Survival Outcomes and Prognostic Indicators in Colorectal Cancer: Findings from a Ghanaian Patient Cohort - Takeaways - MDSpire

Survival Outcomes and Prognostic Indicators in Colorectal Cancer: Findings from a Ghanaian Patient Cohort

  • By

  • Tonnies Abeku Buckman

  • Samuel Asamoah Sakyi

  • Joseph Yorke

  • Jonathan Laryea

  • Bolni Marius Nagalo

  • Michael Nyantakyi

  • Emmanuella Nsenbah Batu

  • Ebenezer Senu

  • Ernest Osei-Bonsu

  • Daniel Sam

  • Emelia Osei Boakye

  • Francis Acheampong

  • Francis Agyemang-Yeboah

  • Christian Obirikorang

  • Emmanuel Acheampong

  • December 29, 2025

  • 0 min

Share

  • 1

    Colorectal cancer (CRC) is the most common cancer in men and the second in women globally, with significant survival disparities between regions.

  • 2

    In sub-Saharan Africa, CRC 5-year overall survival rates are alarmingly low, ranging from 8% to 30%, compared to 65%-72% in high-income countries.

  • 3

    In Ghana, CRC incidence has surged eightfold since 1960, with over half of patients diagnosed at advanced stages, leading to a 5-year survival rate of just 16%.

  • 4

    Limited healthcare infrastructure and socioeconomic barriers in Ghana contribute to late-stage CRC diagnoses, with 60% of cases presenting at stage IV.

  • 5

    The study aims to update CRC survival estimates and identify prognostic factors in Ghana to inform policy initiatives for improved management and outcomes.

Original Source(s)

Survival Outcomes and Prognostic Indicators in Colorectal Cancer: Findings from a Ghanaian Patient Cohort

  • by Tonnies Abeku Buckman, Samuel Asamoah Sakyi, Joseph Yorke, Jonathan Laryea, Bolni Marius Nagalo, Michael Nyantakyi, Emmanuella Nsenbah Batu, Ebenezer Senu, Ernest Osei-Bonsu, Daniel Sam, Emelia Osei Boakye, Francis Acheampong, Francis Agyemang-Yeboah, Christian Obirikorang, Emmanuel Acheampong

  • December 29, 2025

Related Content

FOXA2 in cancer: from fundamental biology to clinical translation

Organ-specific pre-metastatic and metastatic niches in colorectal cancer: “discrepancy in response to immune checkpoint inhibitors in liver and lung metastasis”

Error in Abstract

  • May 15, 2026